

PRESS RELEASE

Basel, Switzerland, May 5th, 2022.

Clinerion's revolutionary ANID technology for de-identification and identification of patient record data in Patient Network Explorer is now patent protected.

New Clinerion patent constitutes a new technology for patient search and identification based on the electronic medical records of patients held by hospitals. The ANID technology involves exclusively the use of de-identified data, unlinked from identifiers, ensuring the privacy and security of patient information.

Highlights:

- ANID is based on fully de-identified patient records, with no use of pseudo-IDs.
- Newly patented technology uses a combination of techniques to match de-identified records with corresponding hospital medical records.
- Newly patented system set-up increases data security and privacy protection.
- The newly patented technology uses de-identified records, but enables the duly authorized clinical trial manager at the hospital to identify eligible clinical trial candidate patients.
- Technology has been in use in the Patient Network Explorer hospital network since 2017.

The newly patented ANID technology, implemented in the hospitals in Clinerion's global hospital network on Patient Network Explorer since 2017, significantly increases the security of private information when using patient medical records to evaluate study feasibility, or identifying patients for enrollment in clinical trials.

The ANID technology exclusively uses fully de-identified records, wherein all identifiable personal information and patient record identifiers have been completely stripped from medical records before use, with no use of pseudo-IDs (pseudonymization). The duly authorized clinical trial manager at the hospital may however still identify eligible patients.

In contrast to a pseudonymization process, which relies on storing identifying information in two separate locations (pseudo-ID and lookup table) and enables identification when the two pieces of the puzzle are combined, ANID technology involves three pieces (de-identified record, structure calculation and lookup table). This provides the fundamental advantage of using fully de-identified data which yet allows patient identification.

While offering a new, enhanced level of data protection, ANID maintains all the advantages of the existing Clinerion technology, such as following HIPAA rules regarding protection against accidental identification. Query results for feasibility requests are stored in the Clinerion secure

private cloud environment, which only sees aggregated counts of the patients which fit the queries. The performance of the Clinerion Patient Network Explorer is not affected, results still appear in real-time and trial recruitment remains more efficient and effective than through conventional methods.

“Patient data security by design is one of the core principles of the whole Patient Network Explorer pipeline,” says Dr. Andreas Walter, Clinerion Chief Technology Officer. “We are proud of having received the ANID patent in addition to another patent for the Patient Network Explorer infrastructure received in 2021.”

“Clinerion has always been very clear that patients are at the center of everything that we do,” says Dr. Barış Erdoğan, Clinerion Chief Executive Officer. “By extension, protection of patient data is also at the forefront of our concerns. This is why we came up with the idea of ANID: to ensure patient privacy.”

The patent EP 2017/069859, “PATIENT RECRUITMENT SYSTEM,” was published in the European Patent Bulletin 2022/16 on April 20th, 2022. The patent was submitted on August 4th, 2017. The related US patent is expected to be published soon.

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We generate real-world data from our global network of partner hospitals for Real World Evidence analyses. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments.

Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion's Patient Network Explorer also provides a platform for integration of diverse patient data sources into real-world data ecosystems. Clinerion's proprietary technologies comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion website: www.clinerion.com

Clinerion's Patient Network Explorer:

www.clinerion.com/index/PatientNetworkExplorerSolutions.html

For more information, please contact:

Le Vin Chin

Director, Head of Marketing & Communications

Clinerion Ltd

Elisabethenanlage 11, 4051 Basel, Switzerland

Tel.: +41 61 865 60 54
media@clinerion.com